Lu et al. demonstrated that AMI is an effective inhibitor of nonalcoholic steatohepatitis (NASH) in LDL receptor-deficient (LDLR−/−) mice with type 2 diabetes mellitus (T2DM) [30]. Here, LDLR is linked to type 2 diabetes mellitus.